AI-powered search

Are there any concerns with the use of IL-23 or IL-17 inhibitors in patients with a history of cutaneous squamous cell carcinoma (cSCC)?

Featuring April Armstrong, MD, MPH | Co-Director |

Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA

| Published October 19, 2021


Related Media

Powered by Polaris TM

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved